Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1

Biochemical and Biophysical Research Communications

Volumn 348, Issue 2, 2006, Pages 618-627

  Jamaluddin, Md Saha ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activator protein 1 (AP1); Aspirin; Electrophoretic mobility shift assay (EMSA); Nonsteroidal anti inflammatory drugs (NSAIDs); Urokinase (uPA); Urokinase type plasminogen activator receptor (uPAR)

Indexed keywords

ACETYLSALICYLIC ACID; HISTONE H4; LUCIFERASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FRA 1; UROKINASE RECEPTOR; VITRONECTIN;

ACETYLATION; ARTICLE; CANCER CELL; CELL MIGRATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN GENOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RECEPTOR UPREGULATION;

ASPIRIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; HUMANS; INDOMETHACIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, CELL SURFACE; TRANSCRIPTION FACTOR AP-1; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 33746864855     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.098     Document Type: Article

References (48)

1. Duffy M.J., and Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37 (2004) 541-548
2. Stoppelli M.P., Tacchetti C., Cubellis M., Corti A., Hearing V., Cassani G., Appella E., and Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45 (1986) 675-684
3. Andreasen P.A., Kjøller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 (1997) 1-22
4. Busso N., Masur S.K., Lazega D., Waxman S., and Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126 (1994) 259-270
5. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., and Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15 (1996) 1572-1582
6. Ossowski L., and Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35 (1983) 611-619
7. Mazar A.P. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anti Cancer Drugs 12 (2001) 387-400
8. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?. Immunol. Today 18 (1997) 415-417
9. Wang Y., Liang X., Wu S., Murrell G.A., and Doe W.F. Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int. J. Cancer 92 (2001) 257-262
10. Soravia E., Grebe A., De Luca P., Helin K., Suh T.T., Degen J.L., and Blasi F.A. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood 86 (1995) 624-635
11. Dang J., Boyd D., Wang H., Allgayer H., Doe W.F., and Wang Y. A region between -141 and -61 bp containing a proximal AP1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Euro. J. Biochem. 264 (1999) 92-99
12. Wang Y., Dang J., Wang H., Allgayer H., and Boyd D. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Euro. J. Biochem. 267 (2000) 3248-3254
13. Lengyel E., Wang H., Stepp E., Juarez J., Wang Y., Doe W., Pfarr C., and Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 271 (1996) 23176-23184
14. Allgayer H., Wang H., Wang Y., Heiss M.M., Bauer R., Nyormoi O., and Boyd D. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2a-related factor. J. Biol. Chem. 274 (1999) 4702-4714
15. Lund L.R., Ellis V., Ronne E., Pyke C., and Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem. J. 310 (1995) 345-352
16. Mandriota S.J., Seghezzi G., Vassalli J.-D., Ferrara N., Wasi S., Mazzieri R., Mignatti P., and Pepper M.S. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem 270 (1995) 9709-9716
17. Pepper M.S., Matsumoto K., Nakamura T., Orci L., and Montesano R. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J. Biol. Chem. 267 (1992) 20493-20496
18. Pepper M.S., Sappino A.P., Stocklin R., Montesano R., Orci L., and Vassalli J.D. Upregulation of urokinase receptor expression on migrating endothelial cell. J. Cell Biol. 122 (1993) 673-684
19. Lund L.R., Romer J., Ellis V., Blasi F., and Dano K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J. 10 (1991) 3399-3407
20. Lund L.R., and Dano K. Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells. FEBS Lett. 298 (1992) 177-181
21. Stoppelli M.P., Corti A., Soffientini A., Cassanni G., Blasi F., and Assoian R. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA 82 (1985) 4939-4943
22. Wang Y., Jones C.J., Dang J., Liang X., Olsen J.E., and Doe W.F. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 353 (1994) 138-142
23. Dang J., Wang Y., and Doe W. Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells. FEBS Lett. 359 (1995) 147-150
24. Gilman A.G., Rall T.W., Nies A.S., and Taylor P. editors. The Pharmacological Basis of Therapeutics (1990), Pergamon Press, New York 638-681
25. Abramson S., Korchak H., Ludewig R., Edelson H., Haines K., Levin R.I., Herman R., Rider R., Kimmel S., and Weissmann G. Modes of action of aspirin-like drugs. Proc. Natl. Acad. Sci. USA 86 (1985) 7227-7231
26. Goel A., Chang D.K., Ricciardiello L., Gasche C., and Boland C.R. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 1 (2003) 383-390
27. Arber N. Do NSAIDs prevent colorectal cancer?. Can. J. Gastroenterol. 4 (2000) 299-307
28. Brooks P.M., and Day R.O. Nonsteroidal antiinflammatory drugs differences and similarities. N. Engl. J. Med. 324 (1991) 1716-1725
29. Terdiman J.P. Aspirin curbs colon polyps. But for many, bleeding risks may offset benefits. Health News 5 (2003) 1-2
30. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Curhan G.C., and Fuchs C.S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294 (2005) 914-923
31. Wang H., Yang L., Jamaluddin Md.S., and Boyd D.D. The kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J. Biol. Chem. 279 (2004) 22674-22683
32. Yan C., Wang H., Toh Y., and Boyd D.D. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J. Biol. Chem. 278 (2003) 2309-2316
33. Yan C., Wang H., Aggarwal B., and Boyd D.D. A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-kappaB motif drives the transition from a repressed to an activated state of gene expression. FASEB J. 18 (2004) 540-541
34. 2+. FEBS Lett. 192 (1985) 189-193
35. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96 (1999) 7563-7568
36. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12 (1998) 599-606
37. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
38. Meade T.W. Aspirin and Other Salicylates. In: Vane J.R., and Botting R.M. (Eds) (1992), Chapman and Hall Ltd., London 321-353
39. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
40. Thun M.J. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev. 13 (1994) 269-277
41. Marnett L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52 (1992) 5575-5589
42. Vane J. Towards a better aspirin. Nature 367 (1994) 215-216
43. Weissmann G. Aspirin Sci. Am. 264 (1991) 84-90
44. Rainsford K.D. Aspirin and the Salicylates (1984), Butterworths & Co., Boston, MA
45. Ahnen D.J. Colon cancer prevention by NSAIDs: what is the mechanism of action?. Eur. J. Surg. 164 Suppl. 582 (1998) 111-114
46. Collen D. The plasminogen (fibrinolytic) system. Thromb. Haemost 82 (1999) 259-270
47. Wang H., Hicks J., Khanbolooki P., Kim S.J., Yan C., Wang Y., and Boyd D.D. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am. J. Pathol. 163 (2003) 453-464
48. Strater J., Wedding U., Barth T.F.E., Koretz K., Elsing C., and Moller P. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology 110 (1996) 1776-1784